Recommendations for Improving Discharge-Related Care Following a COPD Exacerbation: An Expert Panel Consensus with Emphasis on Low- and Middle-Income Countries
- PMID: 40260081
- PMCID: PMC12010079
- DOI: 10.2147/COPD.S502971
Recommendations for Improving Discharge-Related Care Following a COPD Exacerbation: An Expert Panel Consensus with Emphasis on Low- and Middle-Income Countries
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) continue to place a considerable disease and financial burden on both patients and healthcare systems, particularly in low- and middle-income countries (LMICs). Therefore, preventing future exacerbations remains a key treatment goal. However, gaps remain in the standard of COPD care following exacerbations, despite the availability of evidence-based recommendations providing guidance on discharging patients from hospital or emergency department (ED) after a COPD exacerbation. To better understand these gaps in clinical practice, an advisory board meeting of 13 international pulmonologists was convened in September 2022, with the principal objective to formulate and recommend an evidence-based hospital discharge protocol following a COPD exacerbation, with a particular focus on LMICs. Based on identified gaps in COPD care, recommendations for alleviating the burden of exacerbations were proposed, which could be delivered as a discharge protocol for implementation in hospitals and/or ED. Following a review of the available clinical evidence, including an online survey of 11 pre-meeting questions and 5 additional questions discussed during the meeting, the key unmet needs identified by the experts included poor integration of standardized protocols in routine clinical practice, failure to ensure consistent delivery of post-discharge care, and lack of efficiently functioning healthcare systems. A protocol was formulated for delivery as part of a disease management program involving an interdisciplinary approach and a care bundle, aiming to address gaps in discharge-related care by determining the likelihood of readmission and optimizing maintenance treatment plans based on assessment of symptoms and future exacerbation risk. This can provide holistic care following hospital/ED discharge and personalized treatment plans by advocating referral to a specialist. To ensure wide-ranging uptake, implementation of a discharge protocol will need to be tailored to local healthcare settings by conducting feasibility studies, standardizing clinical pathways and healthcare policies, and engaging relevant stakeholders.
Keywords: chronic obstructive pulmonary disease; discharge protocol; emergency department; exacerbation; hospital.
© 2025 Rendon et al.
Conflict of interest statement
Adrian Rendon received payment or honoraria for lectures, presentations, speaker bureaus, and manuscript writing or educational events from AstraZeneca, Chiesi, GlaxoSmithKline, and Sanofi. Susana Luhning received honorarium as speaker and travel expenses from GSK and AstraZeneca. Philip Bardin conducted educational lectures for GSK, AZ, BI, Chiesi, and Sanofi, with funds donated to a research charity (Monash Lung and Sleep Institute). Carlos Andrés Celis-Preciado received support to attend meetings, and grants, personal payment, and payment to his employer for educational and advisory work from AstraZeneca, Sanofi, and GSK that make medicines to treat COPD. Mark Cohen-Todd was a consultant and member of advisory boards for GSK, BI, and AstraZeneca, and has received honorarium as speaker and travel expenses from GSK, BI, AstraZeneca, and Luminova/Novartis. Ahmad Izuanuddin Ismail received research grant, support to attend meetings, and honoraria from AstraZeneca. Terence Seemungal received honoraria from AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim for lectures given at meetings and to attend international meetings. Nurdan Köktürk received research grant and honoraria from AstraZeneca. John R Hurst received support to attend meetings and grants and personal payment and payment to his employer for educational and advisory work from pharmaceutical companies that make medicines to treat COPD. The remaining authors report no conflicts of interest in this work.
Figures
Similar articles
-
Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2016 Dec 19;12(12):CD005074. doi: 10.1002/14651858.CD005074.pub4. Cochrane Database Syst Rev. 2016. PMID: 27990628 Free PMC article.
-
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2. Cochrane Database Syst Rev. 2017. PMID: 28777450 Free PMC article.
-
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD005305. doi: 10.1002/14651858.CD005305.pub4. Cochrane Database Syst Rev. 2016. PMID: 27930803 Free PMC article.
-
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013343. doi: 10.1002/14651858.CD013343.pub2. Cochrane Database Syst Rev. 2022. PMID: 36373977 Free PMC article.
-
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2021 Jul 20;7(7):CD013196. doi: 10.1002/14651858.CD013196.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693988 Free PMC article.
References
-
- World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD); 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pul...). Accessed November 14, 2023.
-
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD; 2024. Available from: https://goldcopd.org. Accessed January 14, 2024.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical